NEW YORK, Feb. 22, 2006 (PRIMEZONE) -- Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview(R) (EIO(r)) on Worcester, Massachusetts-based Advanced Cell Technology, Inc. (OTCBB:ACTC). The full 60-page report can be found at (www.crystalra.com), or on Advanced Cell Technology's web site, (www.advancedcell.com).
Advanced Cell Technology, Inc. ("Advanced Cell" or "the Company") is a biotechnology company applying human embryonic stem (ES) cell technology to the emerging field of regenerative medicine. Regenerative medicine refers to "cell therapy", or treatments that are founded on the concept of producing new cells to replace malfunctioning or damaged cells as a vehicle to treat disease and injury.
Advanced Cell's technologies are currently in the pre-clinical research stage, with the goal of commercializing their use in treating a wide array of chronic degenerative diseases, and in regenerative repair of acute injuries and conditions such as trauma, infarction, and burns. Advanced Cell believes that these reprogramming technologies could produce cells that would maximize the potential for effective use as transplants for replacing diseased or destroyed cells in human patients. These technologies may also avoid reliance on more limited approaches that involve the use of cell lines that may not be histocompatible with the patient, or therapies based upon the use of adult stem cells.
Advanced Cell's research is focused within three core areas: (1) Cellular Reprogramming, which enables the transformation of a patient's own cells into ES cells, which can then be differentiated into specific cells for therapies for a variety of diseases, (2) a Reduced Complexity Library (RCL), enabling production of histocompatible stem cell lines for "off-the-shelf" deployment to treat acute disease in time-critical situations, which are not amenable to reprogramming technologies, and (3) Stem Cell Differentiation, which is designed to control the differentiation and re-differentiation of stem cells into specific cell types, such as hematopoetic, myocardial, skin, retinal, and neuronal cells for therapeutic applications.
To date, the Company has announced its focus on three product programs to develop therapeutics for indications in the eye, skin, and blood. Advanced Cell is headquartered in Worcester, Massachusetts, where the Company houses a Good Manufacturing Practices (GMP)-capable facility to manufacture product for preclinical and clinical testing. The Company also has a facility in Alameda, California, which includes 10,000 square feet of GMP-capable production facilities.
About Crystal Research Associates, LLC
Crystal Research Associates, LLC is an independent research firm that provides institutional-quality fee-based research to small and mid-cap companies. The Company's unique and novel product, the Executive Informational Overview(R) (EIO(R)), is free of investment ratings, target prices, and forward-looking financial models. The EIO(R) presents a crystal-clear, detailed report on a company (whether public or private) in a manner that is easily understood by the Wall Street financial community. The EIO(R) details a company's product/technology/service offerings, market size(s), key intellectual property (IP), leadership, growth strategy, competition, risks, audited financial statements, key events and other such fundamental information. Crystal Research Associates has offices in New York City, Delray Beach, Montreal, and Toronto. Crystal Research Associates has been compensated by Advanced Cell Technology in cash of $35,000 and 150,000 warrants to purchase the Company's common stock. Please see back of report for complete Company disclosures.
Forward-Looking Safe Harbor Statement
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of the Company's technology, opportunities for the Company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of the Company's intellectual property, and economic conditions generally. Additional information on potential factors that could affect results and other risks and uncertainties are detailed from time to time in the Company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2005.
These statements, and other forward-looking statements, are not guarantees of future performance and involve risks and uncertainties. Crystal Research Associates, LLC assumes no obligation to update any of the forward looking statements in this release.